MentionFox
Home › Stakes › Monopar Therapeutics
5%+ stakes · Schedule 13D and 13G

Monopar Therapeutics: 5%+ holders

Who has reported owning 5% or more of Monopar Therapeutics, from Schedule 13D and 13G filings: each holder's stake as filed, the timeline, and the purpose each 13D states, quoted.

At 5% or more3
Filings11
Latest filing2026-08-12

Monopar Therapeutics has 11 Schedule 13D or 13G filings on record since 2025-08-14. 3 holders' latest filing reports 5% or more of common stock, $0.001 par value. Each figure below is the holder's own, as filed, with the filing linked.

Holders

HolderPercentSharesLatestEvent date
Janus Henderson Group Plc19.5%1,287,368SCHEDULE 13G/A, 2025-11-142025-09-30
RA Capital Management, L.P.9.9%667,632SCHEDULE 13G/A, 2026-02-172025-12-31
AstraZeneca PLC7.8%522,667SCHEDULE 13G/A, 2026-02-062025-12-31
Adage Capital Management, L.P.4.76%324,195SCHEDULE 13G/A, 2026-08-122026-06-30
Saturn V Capital Management LP4.7%313,384SCHEDULE 13G/A, 2026-08-122026-06-30
Tactic Pharma LLC4.5%0SCHEDULE 13D/A, 2026-01-302026-01-28

Timeline

FiledHolderPercentFiling
2025-08-14Janus Henderson Group Plc19.2%SCHEDULE 13G/A
2025-09-24Tactic Pharma LLC7.5%SCHEDULE 13D/A
2025-11-14RA Capital Management, L.P.9.9%SCHEDULE 13G/A
2025-11-14Janus Henderson Group Plc19.5%SCHEDULE 13G/A
2026-01-30Tactic Pharma LLC4.5%SCHEDULE 13D/A
2026-02-06AstraZeneca PLC7.8%SCHEDULE 13G/A
2026-02-17RA Capital Management, L.P.9.9%SCHEDULE 13G/A
2026-05-13Adage Capital Management, L.P.6.23%SCHEDULE 13G/A
2026-05-15Saturn V Capital Management LP5.2%SCHEDULE 13G
2026-08-12Adage Capital Management, L.P.4.76%SCHEDULE 13G/A
2026-08-12Saturn V Capital Management LP4.7%SCHEDULE 13G/A

Tools for this story

Each opens in a new tab, filled in for Monopar Therapeutics. With no account yet, you sign up free and land on the result.

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

Cite this page

Permanent URL: https://mentionfox.com/stakes/monopar-therapeutics
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Monopar Therapeutics 5%+ holders: 3 at 5% or more, largest Janus Henderson Group Plc 19.5%. MentionFox, 2026-09-27. https://mentionfox.com/stakes/monopar-therapeutics